Facebook
Twitter
LinkedIn
Forward
Continuous Drug Delivery: Advancements in nAMD and DME (CME Webcast)
Activity Description and Purpose
This program provides retina specialists and other ophthalmologists caring for patients with neovascular age-related macular degeneration and diabetic macular edema a comprehensive overview of sustained-release therapies for retinal diseases. Learners will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the port delivery system with ranibizumab, and emerging options, such as tyrosine kinase inhibitors and gene therapies. Technical considerations for optimizing the safety and efficacy of sustained delivery will be detailed, with a specific focus on port delivery system surgical implantation and refill-exchange procedures. Through case-based discussions, learners will evaluate patient-specific characteristics to determine the appropriate implementation of sustained delivery platforms, considering factors, such as treatment history, ocular comorbidities, and individual patient needs, to select optimal treatment approaches for neovascular age-related macular degeneration and diabetic macular edema.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Appraise the latest data regarding the safety and efficacy of sustained delivery platforms for retinal diseases
- Identify technical considerations to optimize the safety and efficacy of sustained delivery therapies for retinal diseases
- Evaluate patient-specific characteristics when considering implementation of sustained delivery platforms for retinal diseases
Faculty
 | Carl D. Regillo, MD, FACS (Co-Chair) |
 | Margaret A. Chang, MD, MS (Co-Chair) Retinal Consultants Medical Group Sacramento, California |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Margaret A. Chang, MD, MS, is a consultant for AbbVie Inc, Astellas Pharma Inc, Boehringer Ingelheim International GmbH, EyePoint Pharmaceuticals, Genentech, Inc, Ocular Therapeutix, Inc, Oculis, Ollin Biosciences, Inc, Opthea, Regenxbio Inc, and Zeiss; is on the speakers bureau for Genentech, Inc; and is a contracted researcher for Alexion Pharmaceuticals, Inc, EyeBio, Kodiak Sciences Inc, Mylan NV, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, OcuTerra Therapeutics, Outlook Therapeutics, Inc, and Viatris Inc.
Carl D. Regillo, MD, is a consultant for 4DMT, Adverum, Allergan, Annexon Inc, Apellis Pharmaceuticals, Aviceda Therapeutics, Bausch & Lomb Incorporated, Clearside Biomedical, Inc, Cognition Therapeutics, Inc, EyePoint Pharmaceuticals, Genentech, Inc, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kodiak Sciences Inc, Lineage Cell Therapeutics, Inc, Merck & Co., Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Ocugen, Inc, Ocuphire Pharma, OcuTerra Therapeutics, Opthea, Ray Therapeutics, Regenxbio Inc, Stealth BioTherapeutics Inc, Théa Pharma Inc, and Zeiss; is a contracted researcher for 4DMT, Adverum, Allergan, Annexon Inc, Apellis Pharmaceuticals, Astellas Pharma Inc, EyePoint Pharmaceuticals, Genentech, Inc, Gyroscope, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kodiak Sciences Inc, Lineage Cell Therapeutics, Inc, NGM Biopharmaceuticals, Notal Vision, Novartis Pharmaceuticals Corporation, Ocugen, Inc, OcuTerra Therapeutics, Opthea, Regeneron Pharmaceuticals, Inc, and Regenxbio Inc; has stocks options that have not been exercised in Aviceda Therapeutics; and has stock options in Ocugen, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Genentech, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at [email protected].
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.
This CME activity is copyrighted to MedEdicus LLC ©2025. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 335.1
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation